Flipper is talking about (and estimating) manual production(numbers I disagree with), which makes no sense anymore. Why even discuss manual capacity after yesterday’s PR? It’s irrelevant.
NWBO has clearly shifted its commercial manufacturing strategy. They changed direction because of market conditions mainly cost-effectiveness and reimbursement pressures. Manual production can’t survive in a NICE-driven market at £40–50k per treatment. Flaskworks can.
So any manual-capacity estimate is outdated before the sentence is finished. Apparently Flipper ignores yesterday's PR
Market Data 
Markets 
AI
